Article

Alcon proceeds with WaveLight deal

Alcon Inc. had gained control of 76.9% of WaveLight's approximately 6.6 million issued and outstanding shares as of Sept. 28.

Huenenberg, Switzlerland-Alcon Inc. had gained control of 76.9% of WaveLight's approximately 6.6 million issued and outstanding shares as of Sept. 28. The German Security Purchase and Take-over Act also required an additional 2-week acceptance period, Sept. 29 to Oct. 12, during which time Alcon expected to acquire additional shares from WaveLight shareholders.

The company received approvals from the competition authorities in Germany and Austria and was awaiting cartel clearances in China, Cyprus, and Spain prior to closing of the transaction.

"Once we obtain the other regulatory approvals, we can begin the process of integrating WaveLight with Alcon's existing refractive business," said Cary Rayment, Alcon's chairman, president, and chief executive officer (CEO).

Through Sept. 25, about 3.1 million WaveLight shares were tendered to Alcon, equal to 47.1% of the issued and outstanding WaveLight shares. Additionally, Alcon legally acquired 1.96 million WaveLight shares, or 29.9% of the issued and outstanding shares, either on the stock market or through direct purchase.

"Alcon's friendly takeover offer is in the best interest of WaveLight shareholders. I am glad that the offer reached such a high level of acceptance," said Max Reindl, WaveLight's CEO.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.